Acurx Pharmaceuticals stock (US00366D1037): Nasdaq price steady as investors eye valuation metrics

Acurx Pharmaceuticals shares on Nasdaq traded modestly higher in the latest session as investors weighed the micro-cap antibiotic developer’s prospects against current valuation metrics and a recent reverse stock split.

Acurx Pharmaceuticals shares traded slightly higher on Nasdaq in the latest regular session, with the stock closing at USD 1.77 on 06/04/2026, according to MarketBeat as of 06/04/2026. The micro-cap biotech, listed under the ticker ACXP in the United States, continues to attract speculative interest around its antibiotic pipeline while operating far below typical large-cap healthcare valuations.

For investors in Germany, Acurx Pharmaceuticals can also be accessed via secondary trading venues such as Tradegate, where the stock is quoted in euros based on the underlying Nasdaq listing, although liquidity and spreads may differ from the US home market.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Acurx Pharmaceuticals, Inc.
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: Staten Island, United States
• Core markets: United States and global anti-infectives market
• Key revenue drivers: Development of novel antibiotics for infectious diseases
• Home exchange/listing venue: Nasdaq Capital Market (ACXP)
• Trading currency: USD

Acurx Pharmaceuticals: core business model

Acurx Pharmaceuticals focuses on discovering and developing differentiated antibiotic candidates targeting serious bacterial infections, aiming over time to generate revenues from potential product approvals, partnerships, and licensing deals.

Valuation metrics and multiples for Acurx Pharmaceuticals

As a clinical-stage biotech with no approved products yet, Acurx Pharmaceuticals is currently valued primarily on its pipeline prospects rather than traditional earnings-based metrics, and common ratios such as price-to-earnings or dividend yield are not meaningful at this stage. According to MarketBeat as of 06/04/2026, the company’s shares closed at USD 1.77 on Nasdaq, implying a market capitalization in the micro-cap range that reflects the early development profile and high risk typically associated with small antibiotic developers.

MarketBeat also reports a consensus analyst price target of USD 31.00 for Acurx Pharmaceuticals as of 06/04/2026, based on limited available coverage and implying substantial percentage upside from the current share price if the company can successfully advance its drug candidates through late-stage trials and eventual commercialization. This kind of wide gap between the prevailing market price and published target levels is common in thinly covered micro-cap biotech names, where sentiment can shift quickly in response to clinical or regulatory milestones.

Conclusion

Acurx Pharmaceuticals remains a high-risk, early-stage biotech story on the Nasdaq Capital Market, with its share price of USD 1.77 as of 06/04/2026 underscoring how much future progress is already discounted into a modest micro-cap valuation. The wide gap between the current price and the USD 31.00 consensus target reported by MarketBeat as of 06/04/2026 highlights how sensitive valuation could be to clinical updates, regulatory interactions, or financing developments in the coming periods. For now, the stock’s profile is shaped more by its antibiotic development ambitions and capital-market dynamics than by conventional earnings-based valuation metrics.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.